Tyra Biosciences Files 8-K on Leadership and Compensation Changes
Ticker: TYRA · Form: 8-K · Filed: Dec 1, 2025 · CIK: 1863127
| Field | Detail |
|---|---|
| Company | Tyra Biosciences, Inc. (TYRA) |
| Form Type | 8-K |
| Filed Date | Dec 1, 2025 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0001, $550,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, executive-compensation, corporate-governance
TL;DR
Tyra Biosciences updated leadership and pay structures on Nov 25th.
AI Summary
On November 25, 2025, Tyra Biosciences, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing indicates a shift in corporate governance and potential adjustments to how key personnel are compensated.
Why It Matters
Changes in board composition and executive compensation can signal strategic shifts within the company and impact investor confidence.
Risk Assessment
Risk Level: medium — Changes in executive leadership and compensation can sometimes precede or accompany significant strategic decisions or financial performance shifts.
Key Numbers
- 001-40800 — SEC File Number (Identifies the company's filing with the SEC.)
- 83-1476348 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Tyra Biosciences, Inc. (company) — Registrant
- November 25, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 2656 State Street, Carlsbad, California 92008 (address) — Principal Executive Offices
FAQ
What specific changes were made to the board of directors?
The filing indicates changes related to the 'Departure of Directors or Certain Officers' and 'Election of Directors', but the specific names and details of these changes are not provided in the excerpt.
What are the details of the new compensatory arrangements?
The filing mentions 'Compensatory Arrangements of Certain Officers' as an item of disclosure, but the specific details of these arrangements are not included in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported is dated November 25, 2025.
What is Tyra Biosciences, Inc.'s principal executive office address?
The principal executive offices are located at 2656 State Street, Carlsbad, California, 92008.
What is the SIC code for Tyra Biosciences, Inc.?
The Standard Industrial Classification (SIC) code for Tyra Biosciences, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 1,335 words · 5 min read · ~4 pages · Grade level 13.2 · Accepted 2025-12-01 08:00:13
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share TYRA Nasdaq Global Select
- $550,000 — ar's initial annual base salary will be $550,000. Mr. Ashar will also be eligible to par
Filing Documents
- d57660d8k.htm (8-K) — 29KB
- 0001193125-25-303162.txt ( ) — 142KB
- tyra-20251125.xsd (EX-101.SCH) — 3KB
- tyra-20251125_lab.xml (EX-101.LAB) — 18KB
- tyra-20251125_pre.xml (EX-101.PRE) — 11KB
- d57660d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. TYRA BIOSCIENCES, INC. Date: December 1, 2025 By: /s/ Alan Fuhrman Alan Fuhrman Chief Financial Officer